Neoadjuvant chemoimmunotherapy combined with surgery for patients with non-small-cell lung cancer staged as ⅢA / 中华胸心血管外科杂志
Fenghuan SUN; Jie YANG; Tao GE; Haoran XIA; Jie DAI; Xiaogang LIU; Jiaqi LI; Likun HOU; Liang DUAN; Chunyan WU; Yuming ZHU; Gening JIANG; Peng ZHANG.
Chinese Journal of Thoracic and Cardiovascular Surgery
; (12): 516-520, 2021.
Artículo
en Zh
| WPRIM | ID: wpr-912316
Objective:
To explore the efficacy and safety of neoadjuvant chemoimmunotherapy combined with surgery for stage ⅢA NSCLC patients.Methods:
Six patients with NSCLC who were diagnosed as ⅢA and received two cycles of neoadjuvant chemoimmunotherapy and surgery between September 2019 and January 2020 were described in this study.Results:
Five of them experienced AEs during neoadjuvant therapy. All of them received surgery and achieved an MPR of 50%. No viable tumor cells were found in the tissues of one patient. One patient with a small bronchopleural fistula after lobectomy.Conclusion:
Neoadjuvant chemoimmunotherapy combined with surgery for stage ⅢA NSCLC patients is safe and efficient. Long-term outcomes of neoadjuvant chemoimmunotherapy combined with surgery should be further validated.
Biblioteca responsable:
WPRO
Texto completo
Documentos relacionados